Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 18/20 | 0.80 |
| ▸ | CHUK | O15111 | 15/20 | 0.80 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | BTK | Q06187 | 2/20 | 0.38 |
| ▸ | ITK | Q08881 | 2/20 | 0.38 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.38 |
| ▸ | PLK1 | P53350 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8297242 | 0.89 | IKBKB (1.00) | IKBKBCHUKCDK2JAK2JAK1 | |
| SCHEMBL5083193 | 0.86 | IKBKB (1.00) | IKBKBCHUKCDK2BTKITK | |
| SCHEMBL4983432 | 0.75 | IKBKB (0.67) | IKBKBCHUK | |
| SCHEMBL9601077 | 0.74 | IKBKB (0.58) | IKBKBCHUK | |
| SCHEMBL22145812 | 0.73 | IKBKB (0.56) | IKBKBCHUKCDK2BTKITK | |
| SCHEMBL9603045 | 0.71 | IKBKB (0.72) | IKBKBCHUKCDK2BTKITK | |
| SCHEMBL3495964 | 0.68 | IKBKB (0.51) | IKBKBCHUKJAK2JAK1TYK2 | |
| SCHEMBL13533464 | 0.68 | IKBKB (0.67) | IKBKBCHUKCDK2BTKITK | |
| SCHEMBL8297186 | 0.68 | IKBKB (1.00) | IKBKBCHUK | |
| SCHEMBL4984117 | 0.65 | IKBKB (1.00) | IKBKBCHUKCDK2TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1325009-B1 | AMINO-SUBSTITUTED TETRACYCLIC COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL MYERS SQUIBB CO (US) | 2006-03-08 | — | — | EP | claimed |
| US-6960585-B2 | Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-01 | — | — | US | claimed |
| EP-1325009-A2 | AMINO-SUBSTITUTED TETRACYCLIC COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | Bristol-Myers Squibb Company (US) | 2003-07-09 | — | — | EP | claimed |
| US-20020072523-A1 | Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY | 2002-06-13 | — | — | US | claimed |
| WO-2002028860-A2 | AMINO-SUBSTITUTED TETRACYCLIC COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-04-11 | — | — | WO | claimed |
| EP-1363993-A4 | METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF I$g(k)B KINASE (IKK) | BRISTOL MYERS SQUIBB CO (US) | 2008-11-12 | — | — | EP | disclosed |
| EP-1325009-B1 | AMINO-SUBSTITUTED TETRACYCLIC COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL MYERS SQUIBB CO (US) | 2006-03-08 | — | — | EP | disclosed |
| US-6960585-B2 | Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-01 | — | — | US | disclosed |
| US-6869956-B2 | Methods of treating inflammatory and immune diseases using inhibitors of IκB kinase (IKK) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-22 | — | — | US | disclosed |
| EP-1363993-A2 | METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF I$g(k)B KINASE (IKK) | Bristol-Myers Squibb Company (US) | 2003-11-26 | — | — | EP | disclosed |
| EP-1325009-A2 | AMINO-SUBSTITUTED TETRACYCLIC COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | Bristol-Myers Squibb Company (US) | 2003-07-09 | — | — | EP | disclosed |
| US-20030022898-A1 | Methods of treating inflammatory and immune diseases using inhibitors of IkappaB kinase (IKK) | BRISTOL-MYERS SQUIBB COMPANY | 2003-01-30 | — | — | US | disclosed |
| WO-2002060386-A2 | METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF IλB KINASE (IKK) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-08 | — | — | WO | disclosed |
| US-20020072523-A1 | Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY | 2002-06-13 | — | — | US | disclosed |
| WO-2002028860-A2 | AMINO-SUBSTITUTED TETRACYCLIC COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072523-A1 | Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same | IL4, IL4I1, MSR1 | IKBKB 147/4885CHUK 112/4885CDK2 1158/4885 |
| US-20030022898-A1 | Methods of treating inflammatory and immune diseases using inhibitors of IkappaB kinase (IKK) | NFKBIA, IKBKG, IKBKB | IKBKB 3/4885CHUK 6/4885CDK2 540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.